抄録
Purpose of Review: Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients. Here we will review the recent clinical efficacy and adverse events of immune checkpoint inhibitors for melanoma patients. Recent Findings: The immune checkpoint inhibitors increase confirmed objective response and prolong progression-free and overall survival of the afflicted patients in association with maintaining their quality of life. Although diverse immune-related adverse events occur, most of them are manageable by appropriate immunomodulating agents. Clinical efficacy of immune checkpoint inhibitors continues even after discontinuation of drugs. Summary: Compared with conventional therapeutic options, the immune checkpoint inhibitors appear to prolong the survival of patients with advanced melanoma. Further clinical trials are warranted to determine whether their combinatory use with other treatment options may augment benefits or not.
| 元の言語 | 英語 |
|---|---|
| 記事番号 | 29 |
| ジャーナル | Current Oncology Reports |
| 巻 | 20 |
| 発行部数 | 3 |
| DOI | |
| 出版物ステータス | 出版済み - 3 1 2018 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
これを引用
Melanoma and Immune Checkpoint Inhibitors. / Furue, Masutaka; Ito, Takamichi; Wada, Naoko; Wada, Maiko; Kadono, Takafumi; Hiroshi, Uchi.
：: Current Oncology Reports, 巻 20, 番号 3, 29, 01.03.2018.研究成果: ジャーナルへの寄稿 › 評論記事
}
TY - JOUR
T1 - Melanoma and Immune Checkpoint Inhibitors
AU - Furue, Masutaka
AU - Ito, Takamichi
AU - Wada, Naoko
AU - Wada, Maiko
AU - Kadono, Takafumi
AU - Hiroshi, Uchi
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Purpose of Review: Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients. Here we will review the recent clinical efficacy and adverse events of immune checkpoint inhibitors for melanoma patients. Recent Findings: The immune checkpoint inhibitors increase confirmed objective response and prolong progression-free and overall survival of the afflicted patients in association with maintaining their quality of life. Although diverse immune-related adverse events occur, most of them are manageable by appropriate immunomodulating agents. Clinical efficacy of immune checkpoint inhibitors continues even after discontinuation of drugs. Summary: Compared with conventional therapeutic options, the immune checkpoint inhibitors appear to prolong the survival of patients with advanced melanoma. Further clinical trials are warranted to determine whether their combinatory use with other treatment options may augment benefits or not.
AB - Purpose of Review: Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients. Here we will review the recent clinical efficacy and adverse events of immune checkpoint inhibitors for melanoma patients. Recent Findings: The immune checkpoint inhibitors increase confirmed objective response and prolong progression-free and overall survival of the afflicted patients in association with maintaining their quality of life. Although diverse immune-related adverse events occur, most of them are manageable by appropriate immunomodulating agents. Clinical efficacy of immune checkpoint inhibitors continues even after discontinuation of drugs. Summary: Compared with conventional therapeutic options, the immune checkpoint inhibitors appear to prolong the survival of patients with advanced melanoma. Further clinical trials are warranted to determine whether their combinatory use with other treatment options may augment benefits or not.
UR - http://www.scopus.com/inward/record.url?scp=85044267770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044267770&partnerID=8YFLogxK
U2 - 10.1007/s11912-018-0676-z
DO - 10.1007/s11912-018-0676-z
M3 - Review article
C2 - 29569208
AN - SCOPUS:85044267770
VL - 20
JO - Current Oncology Reports
JF - Current Oncology Reports
SN - 1523-3790
IS - 3
M1 - 29
ER -